Document is current
Any future updates will be listed below
-
Authors
Mantas, Ioannis https://orcid.org/0000-0001-6288-5439
Flais, Ivana
Masarapu, Yuvarani https://orcid.org/0000-0002-3267-2085
Ionescu, Tudor
Frapard, Solène https://orcid.org/0000-0002-2649-7225
Jung, Felix
Le Merre, Pierre https://orcid.org/0000-0003-4205-7411
Saarinen, Marcus
Tiklova, Katarina
Salmani, Behzad Yaghmaeian https://orcid.org/0000-0002-4221-6243
Gillberg, Linda
Zhang, Xiaoqun https://orcid.org/0000-0002-9461-8682
Chergui, Karima
Carlén, Marie https://orcid.org/0000-0003-1658-1631
Giacomello, Stefania https://orcid.org/0000-0003-0738-1574
Hengerer, Bastian https://orcid.org/0000-0002-7811-9795
Perlmann, Thomas
Svenningsson, Per https://orcid.org/0000-0001-6727-3802
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2019-01422)
Vetenskapsrådet (2019-01422)
Knut och Alice Wallenbergs Stiftelse
- License Information
-
More Information
Article History
Received: 10 April 2023
Accepted: 4 September 2024
First Online: 18 September 2024
Competing interests
: I.F. was employee at Boehringer Ingelheim Pharma GmbH & Co. KG during the time of the study. T.I. and B.H. are employees at Boehringer Ingelheim Pharma GmbH & Co. KG. S.F. and S.G. are scientific advisors to 10x Genomics Inc, which holds IP rights to the ST technology. S.G. holds 10x Genomics stocks. All other authors report no competing interests.
